MedTrace Logo

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-01-13

No results posted yet for this study

Summary

To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant.

Conditions

  • Healthy Volunteers

Interventions

DRUG

NPT520-34 (125 mg)

NPT520-34, 125 mg oral capsules (size 1)

DRUG

Placebos (125 mg)

Placebo, 125 mg oral capsules

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Neuropore Therapies Inc.

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, M.D. · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-05
Primary Completion
2019-10-02
Completion
2019-10-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03954600 on ClinicalTrials.gov